Welcome to the corner office! Each month, we’ll turn to a new panel of biopharma executives for insights about leadership and management — and tips for thriving in a roller-coaster industry. To share your views in future columns, please fill out this short form. To suggest questions for our panelists, email STAT Plus Editor Liz Cooney. This month, we asked:

How do you coach your team to respond to setbacks?

Emily Leproust, CEO of Twist Bioscience, San Francisco, Calif.: At Twist Bioscience, one of our guiding principles is grit, which we define as passionate drive and fierce determination. By demonstrating grit, we have built a culture of innovation and excellence, which, by necessity requires experimentation. Experimentation results in success but also in setbacks, which we must allow for in a way that is safe and encourages risk-taking.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Nice words, but 1) your coaching will have to distract your team from fear based furiously updating their resumes and 2) everyone will be searching for scapegoats when, on their upcoming interviews they are asked why your company’s drug failed. Since I was in clinical development it was NEVER the fault of my excellent protocol designs; better to crucify the nameless, faceless statisticians who blew the sample size calculations, or the bozos in regulatory affairs who gave you bad advice.

Your daily dose of news in health and medicine

Privacy Policy